Bristol-Myers Squibb

Credit Suisse Healthcare Conference

Murdo Gordon

Head, Worldwide Markets

November 10, 2015

Forward-Looking Information

This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company's most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

This presentation also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items or foreign exchange effects. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company's website at www.bms.com.

Our Strategic Foundation



People helping patients in their fight against serious disease

BMS: Poised for Growth

- Significant growth opportunity driven by I-O and Eliquis
- Strategic investments behind growth brands
- Advancing a diverse and innovative pipeline
- Balanced approach to capital allocation
- Focused business development

Strong Q3 Market Performance

Eliquis™ apixaban — $466M

ORENCIA® (abatacept) — $484M ↑16%

Daklinza™ (daclatasvir) 60 mg tablets
Sunvepra™ (asunaprevir) 100 mg capsules — $402M

SPRYCEL™ dasatinib 100 mg tablets — $411M ↑16%

OPDIVO™ (nivolumab) INJECTION FOR INTRAVENOUS USE 10 mg/mL — $305M

YERVOY™ (ipilimumab) Injection for intravenous infusion — $240M ↓25%

Percentages reflect Q3 15 vs. Q3 14 and exclude impact of foreign exchange. Eliquis, Hep-C, and Opdivo growth rates exceed 100%.

Q3 YTD Sales of $1.1B

Daklinza™ (daclatasvir) 60 mg tablets

Sunvepra™ (asunaprevir) 100 mg capsules

- Focused on challenging-to-treat patient populations
- Capitalizing on opportunity within each market
  - Japan: strong sales in Genotype 1
  - US/EU: Daklinza in Genotype 3; supplemental filings underway
- Evolving competitive landscape

Sunvepra not approved in the U.S. or EU.

Eliquis™ apixaban On track to become the leading NOAC





Eliquis AF/VTE-Tx Pradaxa Total Xarelto AF/VTE-TX Savaysa Total

Note: Eliquis and Xarelto (all form strengths) are factored for AF and VTE-Tx indications. Pradaxa and Savaysa are unfactored and include volume across all approved indications. Source: IMS SDI VECTOR. NBRx (New to Brand Rx) = Naïve + Switch to Rx.

Realizing the Transformational Potential of I-O

- Four Phase 3 studies stopped early
- Global approvals in melanoma and lung
- Investing behind global launches
- Strong early launch trends and commercial execution
- Preparing for potential additional indications

OPDIVO™ (nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

Lung Cancer

- Only PD-1 inhibitor that has demonstrated superior overall survival in 2nd line NSCLC in clinical trials regardless of PD-L1 status
- Broad U.S. label with no requirement for PD-L1 testing
- Rapid adoption in both squamous and non-squamous
- Strong access position in U.S.; negotiations in EU underway
- Multiple front line registrational programs underway in both monotherapy and combination settings

Melanoma

- Yervoy, and now Opdivo, are transforming survival expectations for some patients
- Opdivo + Yervoy Regimen offers meaningful efficacy with tolerable and well-managed safety profile
- Opdivo and Yervoy offer treatment options for broad range of melanoma patients
- Global regulatory filings under review for both 1st line monotherapy and combination

OPDIVO™ (nivolumab)
INJECTION FOR INTRAVENOUS USE 10 mg/mL

Renal Cell Carcinoma

- Checkmate -025 is 4th Opdivo study stopped early due to overall survival benefit
- Data showed improved efficacy and tolerability over a standard of care
- Potential first PD-1 to market in 2nd line RCC
- Phase 3 Opdivo + Yervoy trial underway in 1st line

Confident in Our Future

- Commercial performance of key/new brands
- Investing to capitalize on growth opportunities
- Diversified pipeline to fuel long-term growth
- Disciplined capital allocation

Positioned for long-term success

Bristol-Myers Squibb

Credit Suisse Healthcare Conference

Murdo Gordon

Head, Worldwide Markets

November 10, 2015